We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
Sertraline and venlafaxine: new indication. Prevention of recurrent depression: no advance.
Prescrire International 2005 Februrary
(1) An antidepressant that worked in a depressive episode can be used to prevent recurrences in patients who do not have bipolar disorder. Several antidepressants are at least partially effective in this setting. (2) Sertraline and venlafaxine are now authorised in France for the prevention of recurrent depression. (3) Sertraline and short-acting venlafaxine were both more effective than placebo in single trials (although the data on venlafaxine were somewhat weaker than the data on sertraline). Neither trial has been published in detail. There are no trials comparing sertraline or venlafaxine with other antidepressants in this setting. (4) These trials confirmed the known adverse effect profiles of sertraline and venlafaxine. (5) In practice, these licence extensions have no clinical implications for the management of depression.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app